CClinicalTrials.gg
Status unknownNCT00163839Updated Feb 16, 2012

The Efficacy of a Pseudoallergen-Free Diet in the Treatment of Chronic Idiopathic Urticaria and/or Angioedema

An interventional study of Dietary Therapy in Urticaria and Angioedema, sponsored by Bayside Health. Status unknown at 1 site in Australia. Open to participants aged 21 Years to 75 Years. Per ClinicalTrials.gov, last updated 2012-02-16.

Sponsored by Bayside Health · Not applicable, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Sep 2005), so the status shown — last known as Not yet recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
21 Years to 75 Years
Sex
All
01

Study summary

This study involves investigating the effects of a pseudoallergen-free (active) diet compared with a control (placebo) diet in the treatment of Chronic Idiopathic Urticaria (CIU) and/or Angioedema. The hypothesis is that over a four-week intervention period, the pseudoallergen-free diet will be more effective than the placebo diet in reducing the frequency and severity of CIU and/or Angioedema.

Read the detailed description

The role of dietary pseudoallergens as a trigger for CIU and/or Angioedema is a controversial subject. 'Dietary Pseudoallergy' refers to the mimicking of IgE symptoms (such as rash, itch and swelling) by components of food in the absence of a true IgE mediated response (as diagnosed by RAST and skin prick testing).

The pseudoallergen-free diet excludes a range of naturally occuring chemicals (including salicylates, amines and brewers yeast) in addition to a range of artificial preservatives and additives (for example sulphites and glutamates). The control diet is based on the general dietary guidelines for the management of diabetes (including the principles of healthy eating, low glycemic index choices and a reduced saturated fat intake).

Subjects recruited into the study will have a 3 month history of CIU and/or Angioedema and will be randomly assigned to either the active or control arm of the study in a single blinded fashion. All subjects will be advised to cease antihistamine medication and will receive one-on-one dietary counselling by a Dietitian. The diet to which each subject has been assigned (ie either active or placebo) is to be followed for a 4 week duration. The frequency and severity of CIU and/or Angioedema as well as adherence to the diet are to be measured on both a daily and weekly basis by the subject via the completion of a clinical score card. The results of the score cards will be collated to determine the relative effects of each diet on these conditions.

02

Conditions studied

  • Urticaria
  • Angioedema

Keywords

  • Dietary Intervention
  • Pseudoallergen free diet
03

In context

Angioedema

164 studies on the registry are indexed under Angioedema; 19 are open to participants now.

This study's planned enrollment of 50 is above the median of 44 across 111 interventional studies indexed under Angioedema.

Browse Angioedema studies →

Lead sponsor

Bayside Health is the lead sponsor of 110 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
21 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • English Speaking
  • Aged between 21 to 75 years
  • 3 month history of Chronic Idiopathic Urticaria and/or Angioedema

Exclusion criteria

Exclusion Criteria:

  • age \<21 and >75 years
  • non english speaking
  • systemic lupus erythematosis
  • dysproteinemias
  • thyrotoxicosis
  • vasculitis
  • infection
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Single group
Masking
Single
Enrollment
50 participants (estimated)

Interventions

  • BehavioralDietary Therapy
06

What researchers measure

Primary outcomes

  1. The frequency and severity of CIU and/or angioedema (as determined via a five point rating scale)

Secondary outcomes

  1. The relative use of antihistamines (ie how many, how often)

07

Study locations

1 site
  • Alfred Hospital
    Melbourne, Victoria 3004, Australia
    • Kate L Connell, Masters · Contact · k.connell@alfred.org.au · 0061 3 9276 3063
    • Jo Douglass, FRACP MD · Contact · j.douglass@alfred.org.au · 0061 3 9276 3836
    • Kate L Connell, Masters · Principal investigator
    • Jo Douglass, FRACP MD · Sub investigator
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 16, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00163839
Lead sponsor
Bayside Health
First posted
Sep 14, 2005
Start date
Sep 2005
Last update
Feb 16, 2012

Study contacts

Kate L Connell, Masters
Contact
k.connell@alfred.org.au
0061 3 9276 3063
Jo Douglass, FRACP MD
Contact
j.douglass@alfred.org.au
0061 3 9276 3836
Kate Connell, Masters
principal investigator · Alfred Hospital, Melbourne, Australia
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Sep 2005. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion